Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491447 | 0.85 | — | — | |
| SCHEMBL20558709 | 0.82 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL220802 | 0.78 | — | — | |
| SCHEMBL28496763 | 0.76 | TSHR (0.35) | TSHR | |
| SCHEMBL8123108 | 0.74 | NUDT1 (0.32) | — | |
| SCHEMBL2348023 | 0.74 | — | — | |
| SCHEMBL18203766 | 0.74 | — | — | |
| SCHEMBL457285 | 0.74 | — | — | |
| SCHEMBL7950779 | 0.71 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL4195061 | 0.70 | TSHR (0.30) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797939-B1 | METHOD FOR PURIFYING ORGANIC DIPHOSPHITE COMPOUNDS | BASF SE (DE) | 2018-10-31 | — | — | EP | claimed |
| EP-2797939-A1 | METHOD FOR PURIFYING ORGANIC DIPHOSPHITE COMPOUNDS | BASF SE (DE) | 2014-11-05 | — | — | EP | claimed |
| US-20130225849-A1 | METHOD OF PURIFYING ORGANIC DIPHOSPHITE COMPOUNDS | BASF SE (DE) | 2013-08-29 | — | — | US | claimed |
| WO-2013098368-A1 | METHOD FOR PURIFYING ORGANIC DIPHOSPHITE COMPOUNDS | BASF SE (DE) | 2013-07-04 | — | — | WO | claimed |
| EP-3319951-B1 | METHOD FOR THE HYDROFORMYLATION OF 2-SUBSTITUTED BUTADIENES AND FOR THE PREPARATION OF PRODUCTS DERIVED FROM SAME, PARTICULARLY FROM AMBROX | BASF SE (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-10315975-B2 | Method for the hydroformylation of 2-substituted butadienes and the production of secondary products thereof, especially ambrox | BASF SE (DE) | 2019-06-11 | — | — | US | disclosed |
| EP-2797939-B1 | METHOD FOR PURIFYING ORGANIC DIPHOSPHITE COMPOUNDS | BASF SE (DE) | 2018-10-31 | — | — | EP | disclosed |
| US-20180273458-A1 | METHOD FOR THE HYDROFORMYLATION OF 2-SUBSTITUTED BUTADIENES AND THE PRODUCTION OF SECONDARY PRODUCTS THEREOF, ESPECIALLY AMBROX | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2018-09-27 | — | — | US | disclosed |
| EP-3319951-A1 | METHOD FOR THE HYDROFORMYLATION OF 2-SUBSTITUTED BUTADIENES AND THE PRODUCTION OF SECONDARY PRODUCTS THEREOF, ESPECIALLY AMBROX | BASF SE (DE) | 2018-05-16 | — | — | EP | disclosed |
| US-9108988-B2 | Method of purifying organic diphosphite compounds | BASF SE (DE) | 2015-08-18 | — | — | US | disclosed |
| US-20130225849-A1 | METHOD OF PURIFYING ORGANIC DIPHOSPHITE COMPOUNDS | BASF SE (DE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10315975-B2 | Method for the hydroformylation of 2-substituted butadienes and the production of secondary products thereof, especially ambrox | ALOX12, ALOX15, ALOX5 | TSHR 1333/4885ALDH1A1 683/4885 |
| US-20130225849-A1 | METHOD OF PURIFYING ORGANIC DIPHOSPHITE COMPOUNDS | DCTPP1, DCPS, PPIP5K2 | TSHR 4800/4885ALDH1A1 2007/4885 |
| US-20180273458-A1 | METHOD FOR THE HYDROFORMYLATION OF 2-SUBSTITUTED BUTADIENES AND THE PRODUCTION OF SECONDARY PRODUCTS THEREOF, ESPECIALLY AMBROX | ALOX12, ALOX15, ALOX5 | TSHR 1333/4885ALDH1A1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.